Skip to main content
SpringerLink
Log in

Pramlintide: A new tool in diabetes management

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

The amylin analogue pramlintide acts in concert with insulin to regulate glucose metabolism. It reduces postprandial hyperglycemia by suppressing postprandial glucagon secretion, regulating gastric emptying, and reducing food intake. In clinical use, pramlintide reduces postprandial glycemic excursions and improves A1c without the weight gain and increased risk of hypoglycemia typically seen with intensification of diabetes therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Reda TK, Geliebter A, Pi-Sunyer FX: Amylin, food intake, and obesity. Obes Res 2002, 10:1087–1091.

    Article  PubMed  CAS  Google Scholar 

  2. Buse JB, Weyer C, Maggs DG: Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clin Diabetes 2002, 20:137–144.

    Article  Google Scholar 

  3. Ceriello A, Piconi L, Quagliaro L, et al.: Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care 2005, 28:632–637. Describes the effect of pramlintide in reducing postprandial glycemic excursions and oxidative stress markers, which have been implicated in increased micro-and macrovascular complication risk.

    Article  PubMed  CAS  Google Scholar 

  4. Levetan C, Want LL, Weyer C, et al.: Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care 2003, 26:1–8.

    Article  PubMed  CAS  Google Scholar 

  5. Rayner CK, Samson M, Jones K, Horowitz M: Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001, 24:371–381.

    Article  PubMed  CAS  Google Scholar 

  6. Schvarcz E, Palmer M, Aman J, et al.: Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 1997, 113:60–66.

    Article  PubMed  CAS  Google Scholar 

  7. Amiel SA, Heller SR, Macdonald IA, et al.: The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes. Diabetes Obes Metab 2005, 7:504–516.

    Article  PubMed  CAS  Google Scholar 

  8. Ratner RE, Dickey R, Fineman M, et al.: Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med 2004, 21:1204–1212. Presents pivotal type 1 diabetes study data.

    Article  PubMed  CAS  Google Scholar 

  9. Whitehouse F, Kruger DF, Fineman M, et al.: A randomized study and open-label extension evaluating the long-term ef.cacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002, 25:724–730.

    Article  PubMed  CAS  Google Scholar 

  10. Kolterman O, Burrell T, Shen L, et al.: Initiation of pramlintide using dose-titration in intensively-treated patients with type 1 diabetes resulted in mitigation of nausea and hypoglycemia [abstract]. Diabetes 2003, 52(suppl 2):62-LB.

    Google Scholar 

  11. Symlin (pramlintide acetate) Injection. http://www.symlin. com/pdf/SYMLIN-pi-combined.pdf. Accessed April 25, 2006.

  12. Hollander PA, Levy P, Fineman MS, et al.: Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003, 26:784–790. Presents pivotal type 2 diabetes study data.

    Article  PubMed  CAS  Google Scholar 

  13. Ratner RE, Want LL, Fineman MS, et al.: Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002, 4:51–61.

    Article  PubMed  CAS  Google Scholar 

  14. Maggs DG, Fineman M, Kornstein J, et al.: Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev 2004, 20:55–60.

    Article  PubMed  CAS  Google Scholar 

  15. Karl DM, Wang Y, Lorenzi G, Freeman J S: In an openlabel clinical study pramlintide lowered A1C, body weight, and insulin use in patients with type 2 diabetes failing to achieve glycemic targets with insulin therapy. Diabetes 2005, 55(suppl 1):A12.

    Google Scholar 

  16. Chapman I, Parker B, Doran S, et al.: Effect of pramlintide on satiety and food intake in obese subjects with type 2 diabetes. Diabetologia 2005, 48:838–848.

    Article  PubMed  CAS  Google Scholar 

  17. Turner R, Cull C, Holman R: United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996, 124:136–145.

    PubMed  CAS  Google Scholar 

  18. UK Prospective Diabetes 16: overview of 6 years’ therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group [no authors listed]. Diabetes 1995, 44:1249–1258.

  19. Want LL, Ratner RE, Uwaifo GI: Safety and tolerability of long-term pramlintide therapy. Diabetologia 2004, 47(suppl 2):A44.

    Google Scholar 

  20. Weyer C, Fineman MS, Strobel S, et al.: Properties of pramlintide and insulin upon mixing. Am J Health Syst Pharm 2005, 62:816–822.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Scientific Affairs, MedStar Research Institute, 6495 New Hampshire Avenue, Suite 201, 20783, Hyattsville, MD, USA

    Robert E. Ratner MD

Authors
  1. Laura L. Want RN, MSN, CDE
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert E. Ratner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert E. Ratner MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Want, L.L., Ratner, R.E. Pramlintide: A new tool in diabetes management. Curr Diab Rep 6, 344–349 (2006). https://doi.org/10.1007/s11892-006-0004-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-006-0004-0

Keywords

Search

Navigation